Multicenter, open, prospective, before-after study. Objective: To assess the ecacy and safety of sildena®l therapy for erectile dysfunction in patients with spinal cord injury, and the association between the response to sildena®l and factors such as causes and levels of spinal cord injury, grade of ASIA de®cit, time since injury, orgasmic perception, and degree of baseline erection. Setting: Homes of outpatients of 16 spinal cord injury units in Spain. Method: One hundred and seventy patients with erectile dysfunction secondary to spinal cord injury, from whom baseline data were collected on their sexual function, and who started treatment with sildena®l 50 mg. An ecacy assessment was made by the patient and his partner, and the score of the International Index of Erectile Function (IIEF) was recorded. Results: It was reported by 88.2% of the patients and 85.3% of their partners that treatment with sildena®l had improved their erections, regardless of the baseline characteristics of the spinal cord injury and erectile function. In responders, this improvement was con®rmed by an increase from 12.5 to 24.8 points (P50.001) of the Erectile Function Domain of IIEF. A signi®cant improvement was also seen in patients' satisfaction with sexual activity and general satisfaction derived from sexual life. Preservation of orgasmic perception and a baseline degree of erection of 3 or 4 (P=0.006) were predictors of therapeutic success. No serious adverse events occurred. Conclusion: Sildena®l is an eective, well-tolerated treatment for erectile dysfunction caused by spinal cord injury, regardless of the cause, neurological level, ASIA grade, and time since injury. Sponsorship: Spanish Society of Paraplegia. Spinal Cord (2001) 39, 637 ± 643
Introduction
Erectile dysfunction (ED) was de®ned as the inability to achieve and/or maintain an erection adequate for satisfactory sexual intercourse by the National Institutes of Health Consensus Panel. 1 In spinal cord injuries, organic disorders occur in both sexuality and fertility; however, sexual desire is usually well preserved and is not aected by the injury. Once the injury has occurred, the complex mechanism controlling normal sexual activity will be severely impaired. In men, this will cause a serious impairment in the physical events controlling sexual activity, such as erection, ejaculation and orgasmic perception, leading to a change in the sexual behavior of the patient with spinal cord injury. Eighty per cent of patients with spinal cord injury achieve some type of erection, either re¯ex, psychogenic or mixed. 2, 3 However, the majority of these erections are inadequate for satisfactory sexual intercourse, and some form of treatment is usually required. The relaxation of the corpora cavernosa of the penis through non-adrenergic, non-cholinergic receptors is mediated by nitric oxide (NO) and cGMP. Type 5 phosphodiesterase 5 (PDE5), an enzyme found in the corpora cavernosa of the penis, the smooth muscle of vessels and the platelets, degrades cGMP. 4, 5 Sildena®l is a competitive and selective inhibitor of PDE5 which enhances NO-cGMP-dependent relaxation of the smooth muscle of the corpora cavernosa of the penis, thus improving physiological erection in response to sexual stimula. 6 
Objectives
The objectives of this study were: (1) to assess the eect of sildena®l (Viagra 1 ) on erectile function using the International Index of Erectile Function (IIEF) questionnaire, 7 and assessment by the patient and his partner by the overall ecacy question (OEQ); (2) to establish the safety and tolerability of treatment; and (3) to compare the ecacy between patients with dierent causes and levels of spinal cord injury, degree of ASIA de®cit, 8 time since the start of erectile dysfunction, degree of baseline erection and ejaculation capacity, amongst others.
Methods

Study design
Multicenter, prospective, open, before-after study to assess the eect of sildena®l (Viagra 1 ) on erectile function and its tolerance in 170 patients with spinal cord injury. Since this was a prospective, open study with no control group, each patient acted as his own control in the primary analysis. The following clinical data on the spinal cord injury were obtained at baseline: date, time since occurrence, cause, injury level, degree of ASIA de®ciency, and presence or absence of bulbocavernous re¯ex. The following baseline sexual data were also recorded: orgasmic perception, ejaculatory capacity and characteristics of the erection (for this, we have used a classi®cation of erection adapted to patients with spinal cord injury, regardless of whether erection was re¯ex, voluntary or mixed: Grade 0, absolute impotence; grade 1, tumescence; grade 2, erection inadequate for penetration; grade 3, can penetrate, but erection is not suciently rigid, and grade 4, adequate rigidity, but short-lasting).
Baseline laboratory measurements including complete blood count, biochemistry, electrocardiogram and sitting blood pressure measurement were also made.
Patients
The patients selected were men aged above 18 years with spinal cord injury who had overcome the period of medullary shock, with a stable partner and ED. Reasons for study exclusion were as follows: patients with anatomic deformities of the penis; patients in whom sexual activity was not advised, ie, patients with severe cardiovascular dysfunction such as unstable angina or severe heart failure not controlled with drugs; hypotension (BP490/50 mmHg); recent history (less than 3 months) of stroke or acute myocardial infarction; patients treated with drugs containing nitrates; patients treated with any drug or therapy for ED they were not willing to discontinue during the study; history of retinitis pigmentosa; severe liver or kidney failure, and patients already treated with sildena®l.
Study drug
The patients received sildena®l (Viagra 1 ) at¯exible doses, starting with a 50 mg dose taken as required, approximately 30 ± 45 min before the start of sexual activity; the recommended maximum frequency of administration was once daily. The ®rst two doses were of 50 mg. If the patient considered the response inadequate after the second administration of 50 mg, the dose could be increased to 100 mg.
Administration of concomitant medication to treat the underlying disease of the patients and any other type of drug considered necessary at the investigator's criterion was accepted.
Variables analyzed
During the study, the overall ecacy of treatment perceived by the patient and his partner was assessed using the overall ecacy question (OEQ): Do you think that treatment has improved your erections?, ejaculatory function, the ®nal dose of sildena®l and the response to the International Index of Erectile Function (IIEF) questionnaire. In all patients, treatment tolerability was assessed by recording potential adverse events, and by noting if they caused treatment discontinuation. The IIEF questionnaire was assessed as an overall score before and after treatment, and separated in the dierent dimensions of sexual function: Erectile Function (EF): questions 1 to 5 and 15; Orgasmic Function (OF): questions 9 and 10; Sexual Desire (SD): questions 11 and 12; Satisfaction with Sexual Activity (SS): questions 6 to 8; and Overall Satisfaction derived from Sexual Activity (OS): questions 13 and 14.
Statistical analysis
The statistical methods included a baseline descriptive analysis, overall and of the resulting subpopulations. A Gaussian adjustment was performed in all cases using the Kolmogorov-Smirnov test. The measurement of statistically signi®cant dierences before and after treatment in the score of IIEF questionnaire was tested by the Wilcoxon paired rank test. The Fisher exact test and the chi-squared test were used to assess the association between qualitative variables, and the McNemar test when dichotomic variables were analyzed before and after treatment. The Mann-Whitney test was used to check baseline homogeneity of the subpopulations. A bivariant logistic regression analysis was used to analyze the potential interaction between baseline qualitative and quantitative variables with the response to treatment. An analysis of covariance (ANCOVA) was used to compare the baseline-®nal changes between subpopulations. All tests used for data analysis were performed assuming a maximum a error of 5% (P50.05) and a two-sided contrast. The study was protected against type II errors with a power above 90%. The study was assessed by intention-to-treat.
Results
Study population
The age of the patients ranged from 19 to 65 years, with an overall mean age of 37.3+9.4 years (mean+standard deviation (SD)). Mean duration of ED (time after the spinal injury) was 7.7+6.6 years (range, 0.2 ± 32.7 years). Among the patients, 43.5% were smokers, 32.9% did not drink alcohol, and 18 patients were being treated with intracavernous prostaglandin E1 (10.6%).
The spinal cord injury had been caused by a trac accident in 84 cases (49.4%), by an occupational accident in 23 patients (13.5%), by a casual accident in 41 patients (24.1%), and by another cause: medical/ surgical complications (vascular, tumoral and iatrogenic) in the remaining 22 patients (12.9%). The spinal cord or cauda equina injury was in the cervical spine in 35 patients (20.6%), in the thoracic spine in 99 (58.2%), in the lumbar spine in 30 (17.6%) and at the sacrococcygeal level in the remaining six patients (3.6%).
The injury was located above T10 in 100 subjects (58.8%), and below that level in 70 patients (41.2%). The ASIA classi®cation provided the following results: 94 patients in category A (57.3%), 14 in B (8.5%), 27 in C (16.5%) and 29 in D (17.7%).
At the time of study inclusion, patients had the following grades of erection: nine patients (5.3%) grade 0; 28 (16.5%) grade 1; 50 (29.4%) grade 2; 54 (31.8%) grade 3, and 29 (17.1%) grade 4.
The bulbocavernous re¯ex was present in 132 patients (77.6%). Orgasmic perception was reported by 57 subjects (34.1%), and ejaculation was present in 51 patients (30.5%) before study inclusion.
Ecacy assessment by the patient and partner Among the 170 patients evaluated, 150 (88.2%) reported improved erections with the study treatment (positive response to OEQ or responders). This improvement was con®rmed by 85.3% (99/116) of the partners of the patients (kappa index of agreement of 0.89).
An ecacy analysis was performed of all qualitative and quantitative variables that could be associated with a positive response to treatment, including the response to the IIEF questionnaire. For this analysis, the patients were separated based on the response to OEQ in responders (positive response, n=150, 88.2%) and non-responders (negative response, n=20, 11.8%).
Both groups were statistically homogeneous at baseline in all variables tested, except for the proportion of patients with preserved orgasmic perception, which was signi®cantly higher in responders than in non-responders, and the degree of erection, showing a higher association of grade 3 ± 4 with the eective response to treatment than grade 0 ± 2. The bulbocavernous re¯ex is also present in a greater proportion of responders as compared to nonresponders, but these dierences are not statistically signi®cant.
The distribution of responding and non-responding patients based on the ASIA classi®cation was homogeneous. Category A is the most common classi®ca-tion in both subgroups. The degree of medullary de®cit, either complete (ASIA A) or incomplete (non-A ASIA), showed no signi®cant dierences in the proportion of positive responses to treatment. Table 1 shows the values of these variables, with the corresponding odds ratio and signi®cance P level.
No signi®cant dierences were found in the cause of the spinal cord injury between the two subgroups, which can therefore be considered homogeneous for this variable. The distribution of the causes of spinal cord injury is shown in Table 2 .
No signi®cant dierences were found either between responders and non-responders in the level of spinal cord injury. The thoracic medullary level is the most frequent site of spinal cord injury in both subgroups.
As shown in Table 3 , orgasmic perception was present in a signi®cantly higher proportion of responding than non-responding patients. On average, the presence of orgasmic perception was ®ve times more frequent (with a minimum of 1.1 and a maximum of 22.6 times) in patients with a positive response to sildena®l (Viagra 1 ) than in non-responders. Thus, the probability of a positive response is multiplied by 5 (with a minimum of 1.1 and a maximum of 22.6) when the patient has orgasmic perception.
On the other hand, it has been seen that the degree of erection of patients at the start of the study shows a signi®cant linear association with a positive response to treatment with sildena®l (Viagra 1 ). In order to establish the degree of association and to assess its intensity by the calculation of the corresponding odds ratio, the patients have been grouped by grade of erection into two subgroups: grades 0 to 2, and grades 3 and 4. Table 4 shows that when patients are grouped in this way, no dierences are seen between the two groups in the proportion of patients responding to sildena®l (Viagra 1 ). However, the percentage of non-responders is signi®cantly higher (P=0.006) in the group with erection grades 0 to 2 than in patients with erection grades 3 and 4.
On average, it can be said that moving from erection grade 0 ± 2 to erection grade 3 and 4 multiplies the probability for a positive response by 4.5 (with a minimum of 1.4 and a maximum of 13.9).
The following ecacy variables were also analyzed:
. response to treatment as measured by the IIEF questionnaire, individually and grouped by dimensions (n=150) . sexual activity assessed as the number of attempts at sexual intercourse and the percentage of successful attempts (n=169) . eective dose of sildena®l (Viagra 1 ) and proportion of patients achieving successful sexual intercourse at the ®rst attempt (n=169) . ejaculatory function (n=158). Tables 5 and 6 show the response to the IIEF questionnaire, separated by total score, by dimensions, and individually by questions. Both subgroups are homogeneous at the baseline. In the group of nonresponders, none of the variables in the IIEF questionnaire is signi®cantly changed by treatment with sildena®l (Viagra 1 ), while in responders, all dimensions and questions of the IIEF signi®cantly improve, causing this change to be also signi®cantly higher in responders than in non-responders in all IIEF variables, except for the sexual desire ®eld (Q11, Q12) and also for Q6 (frequency of attempted sexual intercourse) (Figures 1 and 2 ).
IIEF questionnaire according to the patient's response to OEQ
Attempts at sexual intercourse Information is available for 169 patients. Of these, 147 (87%) reported at least one successful attempt at sexual intercourse. Of the total attempts (603) at sexual intercourse made during the study, 431 (71.5%) were successful.
Assessment of the eective dose of sildena®l (Viagra 1 ) Of the 150 patients with a positive response, 69.8% were taking 50 mg and 30.2%, 100 mg. Over the past 4 weeks, during sexual intercourse, how often were you able to maintain your erection after you had penetrated your partner? Analysis of covariance (ANCOVA) for between-group comparisons of baseline-®nal change, and e Wilcoxon test for within-group baseline-®nal paired comparisons. *P<0.05, **P<0.01, ***P<0.001 when signi®cant dierences exist, ns=not signi®cant Ejaculatory function No signi®cant changes were seen in ejaculatory function after treatment (McNemar, P=1.0). Three patients who had their ejaculatory function preserved before treatment were unable to ejaculate in none of the sidena®l dose administration during the study period. The reason for this was not studied, although it could be due to the low amount of sexual intercourse during study. However, four patients with no ejaculation before treatment with sildena®l (Viagra 1 ) had ejaculation after treatment. These four patients, who responded to treatment, had ages ranging from 34 to 50 years, and the injury level was below T10 in three cases (L3, ASIA A; T11 ASIA C; T11 ASIA B). Time since SCI was more than 12 years in the ®rst three patients and 3 years in the fourth patient. The bulbocavernous re¯ex was present in three cases, and the grade of erection was 3 in three cases and 2 in the remaining one. Finally, two patients had orgasmic perception with ejaculation.
Analysis of safety and tolerance
The safety of treatment was assessed by a simple descriptive analysis of the incidence of adverse events during treatment and their percentages. The safety analysis included all 170 patients receiving at least one tablet of sildena®l (Viagra 1 ). Adverse events were found in 41 of the 170 (24.1%) patients evaluated, of whom 10 had headache, 15 ushing, seven gastrointestinal discomfort, eight nasal congestion, and seven visual disturbances, whereas nine patients reported restlessness, palpitations, hiccup, and dry mouth. These adverse events did not persist with continued treatment.
Adverse events only required treatment discontinuation in one patient (0.59%). The reason was unbearable abdominal pain.
Discussion
The results of this study are consistent with those reported in the scienti®c literature for this type of patient.
Unlike other studies, 9 ± 12 this study has been able to establish factors which allow, with a high statistical signi®cance, to predict a positive response, such as: preserved orgasmic function and erection grades 3 and 4 at baseline.
The patients who assessed their response made it based on the criterion of the achievement of an erection hard enough for penetration and lasting long enough for maintaining satisfactory sexual intercourse. Of these, 88.2% reported an improvement in ED after treatment with sildena®l (Viagra 1 ). To support this, the OEQ for the partner was included. An improvement was also perceived by 85.3% of partners, with a very high kappa index of agreement in responses: 0.89.
Signi®cant dierences in the response were not observed when dierent groups were made by level of SCI, by segments (cervical, thoracic, lumbar and sacrococcygeal and neither cervical, T1-T5, T6-T12, lumbar and sacrococcygeal). Finally we decided to make two groups: injuries above T10 (leaving intact below the injury the sympathetic and parasympathetic centers that control erection) and injuries below T10, because these two groups are better adjusted to the re¯ect response. No signi®cant dierences were found in all groups and the proportion of responders and non-responders was the same. Same results were found when the groups were made by grade of ASIA de®cit, therefore the ®nal groups are ASIA A and Non-A ASIA.
Response to treatment was not modi®ed (as expected) by the cause of injury, or the time since SCI. A high percentage of patients have perceived sildena®l (Viagra 1 ) to be an eective drug for the treatment of ED, regardless of the cause, level and time since the spinal cord injury, and of the ASIA de®cit.
The fact that a patient with L3 level and ASIA A had ejaculated after taking sildena®l (Viagra 1 ) may be explained by the sympathetic center not being aected by the injury. The case of the two patients with T11 injuries are explained because both patients had incomplete SCI that allowed them a bigger stimulation when achieving a maintained erection and therefore ejaculation. In the case of the patient with T4 ASIA A injury, the ejaculation was re¯ex.
Conclusions
The general conclusions that can be drawn after the statistical assessment of this study are as follows: 88.2% of men with ED due to spinal cord injury treated with sildena®l (Viagra 1 ) reported an improvement in ED. This improvement was also perceived by their partners (85.3%), with a very high kappa index of response agreement: 0.89.
A dose of 50 mg of sildena®l (Viagra 1 ) was required by 69.8% of patients to achieve ecacy, whereas the remaining 30.2% required a dose of 100 mg. A little over half of the patients achieved successful sexual intercourse on the ®rst attempt (57.4%).
Signi®cance dierences in the response to treatment were not found in the analysis of the next groups: cause of SCI, level of SCI, time since SCI or ASIA de®cit.
The ecacy of treatment is con®rmed by the response to the IIEF questionnaire. All dimensions and individual questions signi®cantly improved particularly erectile function and, to a lower extent, orgasmic function and sexual desire. Sildena®l (Viagra 1 ) signi®cantly improves the patient's satisfaction with sexual activity and overall satisfaction from sexual life (P50.001).
Of all baseline variables analyzed, the presence of orgasmic perception before treatment (P=0.021) and erection grades 3 and 4 (P=0.006) are signi®cantly associated with a positive response to treatment and, therefore, are factors predicting response.
A preserved bulbocavernous re¯ex is also associated with a positive response to sildena®l (Viagra 1 ), though less strongly than the above variables.
Treatment with sildena®l (Viagra 1 ) is safe and welltolerated. Only one patient discontinued treatment for adverse events.
